Labcorp (NYSE:LH) Director Kerrii Anderson Sells 3,000 Shares

Labcorp Holdings Inc. (NYSE:LH) Director Kerrii Anderson sold 3,000 shares of the firm’s stock in a transaction dated Monday, August 17th. The shares were sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director owned 6,563 shares of the company’s stock, valued at $2,087,165.26. This trade represents a 31.37% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Labcorp Stock Down 0.2%

Shares of NYSE:LH opened at $322.68 on Wednesday. The firm’s 50-day moving average is $288.51 and its two-hundred day moving average is $275.48. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.80 and a quick ratio of 1.53. Labcorp Holdings Inc. has a 1 year low of $244.52 and a 1 year high of $329.47. The firm has a market capitalization of $26.17 billion, a PE ratio of 26.69, a price-to-earnings-growth ratio of 1.84 and a beta of 0.87.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, July 30th. The medical research company reported $4.99 earnings per share for the quarter, beating analysts’ consensus estimates of $4.78 by $0.21. The firm had revenue of $3.73 billion during the quarter, compared to analysts’ expectations of $3.71 billion. Labcorp had a net margin of 6.99% and a return on equity of 16.74%. The business’s quarterly revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the business posted $4.35 earnings per share. Labcorp has set its FY 2026 guidance at 18.100-18.550 EPS. Analysts predict that Labcorp Holdings Inc. will post 18.32 EPS for the current year.

Labcorp Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Shareholders of record on Friday, August 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.9%. Labcorp’s dividend payout ratio is currently 23.82%.

Wall Street Analysts Forecast Growth

LH has been the subject of a number of recent analyst reports. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating and set a $306.00 price target on shares of Labcorp in a report on Friday, July 31st. Truist Financial raised their target price on Labcorp from $320.00 to $350.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Sunday, July 12th. Bank of America upped their price target on Labcorp from $300.00 to $320.00 and gave the company a “buy” rating in a report on Monday, July 13th. Finally, Barclays increased their target price on shares of Labcorp from $290.00 to $320.00 and gave the company an “equal weight” rating in a research report on Thursday, July 30th. Nine equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $330.00.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in the company. REAP Financial Group LLC boosted its holdings in shares of Labcorp by 20.4% in the 4th quarter. REAP Financial Group LLC now owns 218 shares of the medical research company’s stock worth $55,000 after purchasing an additional 37 shares during the period. V Square Quantitative Management LLC lifted its position in Labcorp by 1.7% in the first quarter. V Square Quantitative Management LLC now owns 2,418 shares of the medical research company’s stock worth $645,000 after buying an additional 40 shares during the last quarter. Hilltop Holdings Inc. boosted its stake in Labcorp by 2.6% during the fourth quarter. Hilltop Holdings Inc. now owns 1,631 shares of the medical research company’s stock worth $409,000 after buying an additional 41 shares during the period. Larson Financial Group LLC boosted its stake in Labcorp by 37.5% during the third quarter. Larson Financial Group LLC now owns 154 shares of the medical research company’s stock worth $44,000 after buying an additional 42 shares during the period. Finally, Pinnacle Associates Ltd. raised its stake in shares of Labcorp by 3.9% in the fourth quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock valued at $282,000 after acquiring an additional 42 shares during the period. Hedge funds and other institutional investors own 95.94% of the company’s stock.

About Labcorp

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.